Related Experiment Video
Updated: Aug 7, 2026
Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays
Published on: November 29, 2014
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2
Jianwei Wei1, Qiongyu Shi2, Bang Li1
1Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Abstract:
The histone lysine methyltransferase NSD2 has been recognized as an attractive target for cancer treatment, due to the functional implication of its dysregulation in the initiation and progression of many cancers. Although considerable efforts have been made to develop NSD2 small-molecule inhibitors, highly potent and selective ones are still rarely available till now. Here, we report the discovery of a series of novel NSD2 inhibitors via an extensive SAR exploration of the privileged quinazoline scaffold within compound 8. The most promising compound 42 showed excellent NSD2 enzymatic inhibitory activity and good antiproliferative activity in cells. In addition, it demonstrated favorable pharmacokinetic properties and significantly inhibited the tumor growth in a RS411 tumor xenograft model with good safety. Taken together, compound 42 could be a promising NSD2 inhibitor and deserves further investigation.
Insights
Researchers discovered a novel quinazoline-based compound, compound 42, that effectively inhibits NSD2 enzymes. This promising drug candidate shows potent anti-cancer activity and warrants further investigation for therapeutic development.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- The histone lysine methyltransferase NSD2 is implicated in various cancers.
- Developing potent and selective NSD2 inhibitors is crucial for cancer therapy.
- Existing NSD2 inhibitors lack sufficient potency and selectivity.
Purpose of the Study:
- To discover novel NSD2 inhibitors using a privileged quinazoline scaffold.
- To identify potent and selective small-molecule inhibitors of NSD2.
- To evaluate the anti-cancer potential of newly discovered NSD2 inhibitors.
Main Methods:
- Structure-Activity Relationship (SAR) exploration of quinazoline derivatives.
- Enzymatic assays to determine NSD2 inhibitory activity.
- Cell-based proliferation assays and in vivo tumor xenograft models.
Main Results:
- A series of novel NSD2 inhibitors were identified based on the quinazoline scaffold.
- Compound 42 demonstrated potent NSD2 enzymatic inhibition and antiproliferative effects.
- Compound 42 exhibited favorable pharmacokinetics and significantly inhibited tumor growth in vivo with good safety.
Conclusions:
- Compound 42 is a highly promising NSD2 inhibitor with therapeutic potential.
- The identified quinazoline derivatives represent a valuable class of anti-cancer agents.
- Further preclinical and clinical investigations of compound 42 are warranted.
Related Concept Videos
00:49Ligand Binding and Linkage
01:19Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...